Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

4120 - Brain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers


28 Sep 2019


Poster Display session 1


Tumour Site

Non-Small Cell Lung Cancer


Matthew G Krebs


Annals of Oncology (2019) 30 (suppl_5): v602-v660. 10.1093/annonc/mdz260


M.G. Krebs1, L. Perez2, A. Surinach3, R.C. Doebele4, R. Martina5, M. Martinec2, T. Riehl6, N.J. Meropol7, W. Wong6, G. Crane8

Author affiliations

  • 1 Division Of Cancer Sciences, Faculty Of Biology, Medicine And Health, University Of Manchester And The Christie Nhs Foundation Trust, Manchester Academic Health Science Centre, M20 4BX - Manchester/GB
  • 2 ., F. Hoffmann-La Roche Ltd, 4070 - Basel/CH
  • 3 ., Genesis Research, 07030 - Hoboken/US
  • 4 Thoracic Oncology Research Initiative, University of Colorado, 80045 - Aurora/US
  • 5 Biostatistics, University of Liverpool, L69 3BX - Liverpool/GB
  • 6 ., Genentech, 94080 - South San Francisco/US
  • 7 ., Flatiron Health, New York/US
  • 8 ., F. Hoffmann-La Roche Ltd, AL7 1TW - Welwyn Garden City/GB


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 4120


As new targeted therapies with CNS penetration and activity for non-small cell lung cancer (NSCLC) with ROS1 gene fusions (ROS1+) emerge, there is a need to characterize the disease course of patients (pts) receiving current treatment, especially in relation to CNS metastases (met).


We evaluated an anonymized cohort of ROS1+ NSCLC pts from the Flatiron Health electronic health record (EHR)-derived database of US cancer centers (2011–2018). Descriptive statistics were used for clinical and treatment pattern characterization. Kaplan-Meier curves estimated median overall survival (OS), real-world progression-free survival (rwPFS, using physician documentation in the EHR) and rwPFS in the CNS, from 1st-line treatment (1L) after diagnosis of advanced/metastatic NSCLC (aNSCLC Dx). Due to low numbers of pts in some groups, 95% CI are not reported.


We identified 129 ROS1+ aNSCLC pts who received 1L treatment including crizotinib (n = 52, 40.3%), chemotherapy (n = 34, 26.4%), combination systemic therapy (n = 25, 19.4%), clinical study drug (n = 4, 3.1%), or no treatment (n = 14, 10.9%). For 1L crizotinib (the only approved therapy for ROS1+ NSCLC) after aNSCLC Dx median rwPFS: 8.6 m (95% CI: 6.2–12.1); OS: 19.9 m (95% CI: 15.1–NR). For pts receiving other 1L drugs median rwPFS: 5.9 m (95% CI: 4.1–7.2); OS: 18.1 m (95% CI: 12.9–34.6). There were 24 pts (18%) with CNS met at diagnosis and 20 pts (19%) at follow-up. Most pts with CNS met at or after diagnosis received surgery/radiotherapy (37/44, 84.1%). For CNS met pts who received 1L crizotinib after local treatment (6/11), median rwPFS: 8.0 m; OS: 27 m. From 1L crizotinib, pts with CNS met at follow-up only (10/21 pts with CNS mets who received 1L crizotinib), median rwPFS: 7.2 m; rwPFS-CNS: 9.1 m; OS: 15.1 m. For pts with no CNS mets anytime median rwPFS: 10.0 m; OS: 21.5 m from 1L crizotinib (34/55 pts).


In the US, ROS1+ NSCLC pts receive various 1L treatments after aNSCLC Dx. CNS was a site of metastasis in 44/129 ROS1+ NSCLC pts. Surgery/radiotherapy for CNS mets prior to systemic therapy appeared to result in favorable outcomes, however conclusions on the natural history of cancers with rare mutations rely on very small patient numbers.

Clinical trial identification

Editorial acknowledgement

Laura Vergoz and Charlotte Kennerley, PhD of Gardiner-Caldwell Communications, funded by F. Hoffmann-La Roche.

Legal entity responsible for the study

F. Hoffmann-La Roche.


F. Hoffmann-La Roche.


M.G. Krebs: Advisory / Consultancy, Officer / Board of Directors: Roche, Achilles Therapeutics, Octimet, Janssen; Research grant / Funding (self), Research grant / Funding (institution): AstraZeneca, Bayer, BerGenBio, Blueprint, Carrick, Immutep, Incyte, Janssen, Merck, Octimet, Roche; Travel / Accommodation / Expenses: AstraZeneca, BerGenBio. L. Perez: Research grant / Funding (institution), Shareholder / Stockholder / Stock options: Roche. A. Surinach: Full / Part-time employment: Genesis Research. R.C. Doebele: Shareholder / Stockholder / Stock options: Rain Therapeutics; Advisory / Consultancy: Chair of Scientific Advisory Board for Rain Therapeutics; Honoraria (self): Guardant; Advisory / Consultancy: Pfizer, Trovagene, Ariad, Takeda, AstraZeneca, Genentech/Roche, Ignyta, Loxo, Rain Therapeutics; Research grant / Funding (self), Research grant / Funding (institution): Ignyta, Loxo, Mirati; Licensing / Royalties: Molecular, Rain Therapeutics, GVKbio, Chugai, Loxo, Ignyta, Genentech, Ariad, Foundation Medicine, Black Diamond. M. Martinec: Research grant / Funding (self), Shareholder / Stockholder / Stock options, Full / Part-time employment: F. Hoffmann-La Roche Ltd. T. Riehl: Shareholder / Stockholder / Stock options, Full / Part-time employment: Roche/Genentech. N.J. Meropol: Shareholder / Stockholder / Stock options: Roche; Shareholder / Stockholder / Stock options, Full / Part-time employment: Flatiron Health, Inc. W. Wong: Shareholder / Stockholder / Stock options: Roche; Full / Part-time employment: Genentech. G. Crane: Shareholder / Stockholder / Stock options, Full / Part-time employment: Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.